Biohaven withdraws Troriluzole application to EMA for Spinocerebellar ataxias
In March, Biohaven shared that they have taken the decision to withdraw their new drug application to the European Medicines Agency (EMA) for Troriluzole to treat adults with all Spinocerebellar […]
Biohaven withdraws Troriluzole application to EMA for Spinocerebellar ataxias Read More »
